Happy Holidays From The Far Council -- Proposed Restrictions On Allowable Airfare
Client Alert | 1 min read | 12.21.07
In a proposed change to FAR 31.205-46(b) (72 Fed. Reg. 72325 (Dec. 20, 2007)), the FAR Council is seeking public comments on a proposal to change the standard for allowable airfare from "the lowest customary standard, coach, or equivalent airfare offered during normal business hours" to nothing "in excess of the lowest priced coach class, or equivalent, airfare available to the contractor during normal business hours." While it appears from the comments in the proposed regulation and what is known about the background of this proposal that the principal purpose of the proposal is to measure the unallowable cost attributable to premium airfares by disallowing the excess over the lowest available discounted airfare available, the proposal obviously has the potential for creating serious difficulties for all contractors and all travel where the lowest price "available to the contractor" is determined in an ephemeral internet market that changes literally from minute to minute and depends on a variety of factors including the fliers' willingness to accept advance purchase and minimum stay requirements, restrictions on changes and refundability, and choice of carrier.
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
Client Alert | 4 min read | 10.20.26
California Follows New York’s Lead in Requiring AI “Synthetic Performer” Disclosures in Advertising
